GlassScriptPhysician profile
Marcus Tellez
NPI 1144753773
$84,103.62
in general payments reported to CMS, 2019-2025
63 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $558 · 2021: $4,481 · 2022: $4,529 · 2023: $25K · 2024: $26K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $19K · Travel and Lodging: $7,614 · Education: $25.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,400.00 |
| Food and Beverage | $19,496.17 |
| Travel and Lodging | $7,613.85 |
| Education | $25.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58,776.54 | 2020-2025 | Descovy, Yeztugo, Biktarvy |
| Viiv Healthcare Company | $7,162.70 | 2020-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $3,601.41 | 2020-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Emd Serono, INC. | $1,616.81 | 2020-2025 | Serostim, Serostim |
| Novo Nordisk INC | $1,616.31 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,332.09 | 2021 | |
| Amgen INC. | $1,127.98 | 2020-2025 | Repatha, Otezla, Otezla |
| Janssen Biotech, INC. | $817.26 | 2021-2023 | Symtuza |
| Abbvie INC. | $559.84 | 2022-2025 | Vraylar |
| Theratechnologies INC. | $523.39 | 2021-2025 | Egrifta, Trogarzo |
| Lilly USA, LLC | $516.91 | 2022-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $499.93 | 2021-2025 | Trintellix |
| Janssen Products, LP | $461.91 | 2021-2023 | Symtuza |
| Pfizer INC. | $443.83 | 2021-2025 | |
| Axsome Therapeutics, INC. | $390.14 | 2023-2025 | Auvelity, Sunosi |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Tellez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.